Cardiovascular morbidity and mortality in patients with diabetes in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol
The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Abstract
Background The most suitable antihypertensive drug to reduce the risk of cardiovascular disease in patients with hypertension and diabetes is unclear. In prespecified analyses, we compared the effects of losartan and atenolol on cardiovascular morbidity and mortality in diabetic patients.Methods As part of the LIFE study, in a double-masked, randomised, parallel-group trial, we assigned a group of 1195 patients with diabetes, hypertension, and signs of left-ventricular hypertrophy (LVH) on electrocardiograms losartan-based or atenolol-based treatment. Mean age of patients was 67 years (SD 7) and mean blood pressure 177/96 mm Hg (14/10) after placebo run-in. We followed up patients for at least 4 years (mean 4.7 years [1.1]). We used Cox regression analysis with baseline Framingham risk score and electrocardiogram-LVH as covariates to compare the effects of the drugs on the primary composite endpoint of cardiovascular morbidity and mortality (cardiovascular death, stroke, or myocardial infarction).Findings Mean blood pressure fell to 146/79 mm Hg (17/11) in losartan patients and 148/79 mm Hg (19/11) in atenolol patients. The primary endpoint occurred in 103 patients assigned losartan (n=586) and 139 assigned atenolol (n=609); relative risk 0.76 (95% CI 0.58-.98), p=0.031. 38 and 61 patients in the losartan and atenolol groups, respectively, died from cardiovascular disease; 0.63 (0.42-0.95), p=0.028. Mortality from all causes was 63 and 104 in losartan and atenolol groups, respectively; 0.61 (0.45-0.84), p=0.002.Interpretation Losartan was more effective than atenolol in reducing cardiovascular morbidity and mortality as well as mortality from all causes in patients with hypertension, diabetes, and LVH. Losartan seems to have benefits beyond blood pressure reduction.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“All available BP-lowering drugs can be used, but evidence strongly supports using a renin-angiotensin system (RAS) inhibitor (ACE-I, ARB), particularly in patients with evidence of end-organ damage (albuminuria and left ventricular [LV] hypertrophy).”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [213]
In the citing paper
“In patients with congestive heart failure (CHF), including diabetic subgroups, ARBs have been shown to reduce major CVD outcomes (175–178), and in type 2 patients with significant nephropathy, ARBs were superior to calcium channel blockers for reducing heart failure (179–181).”
From Standards of Medical Care in Diabetes—2009 (2009) · cites this paper as [178]
Citations
Cites
(2000) · New England Journal of Medicine · doi:10.1056/nejm200001203420301 · Cited by 8,663
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Self-citationLewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Global and societal implications of the diabetes epidemic
Zimmet, P., Alberti, K. G. M. M., & Shaw, J. (2001) · Nature · doi:10.1038/414782a · Cited by 5,883
Hansson, L., Zanchetti, A., Carruthers, S. G., Dahlöf, B., Elmfeldt, D., Julius, S., Ménard, J., Rahn, K. H., Wedel, H., & Westerling, S. (1998) · The Lancet · doi:10.1016/s0140-6736(98)04311-6 · Cited by 5,728
Self-citationDahlöf, B., Devereux, R. B., Kjeldsen, S. E., Julius, S., Beevers, G., de Faire, U., Fyhrquist, F., Ibsen, H., Kristiansson, K., Lederballe-Pedersen, O., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08089-3 · Cited by 5,407
Self-citationStamler, J., Vaccaro, O., Neaton, J. D., Wentworth, D., & The Multiple Risk Factor Intervention Trial Research Group (1993) · Diabetes Care · doi:10.2337/diacare.16.2.434 · Cited by 4,063
(1999) · Journal of Hypertension · doi:10.1097/00004872-199917020-00001 · Cited by 3,695
(2000) · PubMed · Cited by 2,095
Research works printed but not linked: 2
- Liu, 2000, Cardiovascular disease and prognosis in adults with glucose disorders: the Strong Heart Study, J Am Coll Cardiol, 35, 263A
- 2002, Diabetic nephropathy, Diabetes Care, 25, S85
Cited by
Items 301–400 of 1,001
Type 2 diabetes mellitus: a cardiovascular perspective
Varughese, G. I., Tomson, J., & Lip, G. Y. H. (2005) · International Journal of Clinical Practice · doi:10.1111/j.1368-5031.2005.00571.x · Cited by 65
Okin, P. M., Devereux, R. B., Harris, K. E., Jern, S., Kjeldsen, S. E., Lindholm, L. H., & Dahlöf, B. (2007) · Hypertension · doi:10.1161/hypertensionaha.107.096818 · Cited by 59
Self-citationApproach to diabetes management in patients with CVD
Lathief, S., & Inzucchi, S. E. (2015) · Trends in Cardiovascular Medicine · doi:10.1016/j.tcm.2015.05.005 · Cited by 58
Renal mitochondrial impairment is attenuated by AT 1 blockade in experimental Type I diabetes
de Cavanagh, E. M. V., Ferder, L., Toblli, J. E., Piotrkowski, B., Stella, I., Fraga, C. G., & Inserra, F. (2008) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00926.2007 · Cited by 54
“Chronic inhibition of the renin-angiotensin system (RAS) can delay the onset and progression of nephropathy in diabetic patients (6, 45, 70), as well as the development of type 2 diabetes in patients with hypertension and high cardiovascular risk (33, 37, 51).”
BackgroundSakuta, T., Morita, Y., Satoh, M., Fox, D. A., & Kashihara, N. (2010) · Arthritis & Rheumatism · doi:10.1002/art.27384 · Cited by 61
Munk, V. C., de Miguel, L. S., Petrimpol, M., Butz, N., Banfi, A., Eriksson, U., Hein, L., Humar, R., & Battegay, E. J. (2007) · Hypertension · doi:10.1161/hypertensionaha.106.080242 · Cited by 54
Metabolic syndrome in relationship to type 2 diabetes and atherosclerosis
Tkáč, I. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2005.03.002 · Cited by 59
Meakins, J., & Scriver, W. D. M. (2013) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2013.02.025 · Cited by 55
Stroke in Patients With Diabetes and Hypertension
McFarlane, S. I., Sica, D. A., & Sowers, J. R. (2005) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2005.04379.x · Cited by 65
Diabetic Brain Damage in Hypertension: Role of Renin-Angiotensin System
Kario, K., Ishikawa, J., Hoshide, S., Matsui, Y., Morinari, M., Eguchi, K., Ishikawa, S., & Shimada, K. (2005) · Hypertension · doi:10.1161/01.hyp.0000163460.07639.3f · Cited by 59
Renal and Cardiovascular Protection in Type 2 Diabetes Mellitus: Angiotensin II Receptor Blockers
Deferrari, G., Ravera, M., Deferrari, L., Vettoretti, S., Ratto, E., & Parodi, D. (2002) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000032544.37147.ae · Cited by 53
Effect of Renal Artery Stenting on Left Ventricular Mass: A Randomized Clinical Trial
Marcantoni, C., Zanoli, L., Rastelli, S., Tripepi, G. L., Matalone, M., Mangiafico, S., Capodanno, D., Scandura, S., Landro, D. D., Tamburino, C., et al. (2012) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.01.022 · Cited by 52
Pearce, W. H., Zarins, C. K., Bacharach, J. M., & for Writing Group 6 (2008) · Circulation · doi:10.1161/circulationaha.108.191176 · Cited by 57
Bloomgarden, Z. T. (2005) · Diabetes Care · doi:10.2337/diacare.28.3.745 · Cited by 64
Neutel, J. M. (2008) · Current Medical Research and Opinion · doi:10.1185/03007990802262457 · Cited by 60
Hospitalizations, Nursing Home Admissions, and Deaths Attributable to Diabetes
Russell, L. B., Valiyeva, E., Roman, S. H., Pogach, L. M., Suh, D.-C., & Safford, M. M. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1611 · Cited by 52
Part 1. Uric acid and losartan
Sica, D. A., & Schoolwerth, A. C. (2002) · Current Opinion in Nephrology & Hypertension · doi:10.1097/00041552-200209000-00001 · Cited by 52
Beta-blockers for hypertension
Wiysonge, C. S., Bradley, H. A., Volmink, J., Mayosi, B. M., Mbewu, A., & Opie, L. H. (2012) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002003.pub4 · Cited by 51
Management of the Metabolic Syndrome
Hafidh, S. A. S., Senkottaiyan, N., Alpert, M., & Villarreal, D. (2005) · The American Journal of the Medical Sciences · doi:10.1097/00000441-200512000-00013 · Cited by 56
McLean, D., Simpson, S. H., McAlister, F. A., & Tsuyuki, R. T. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70304-x · Cited by 57
Tolerability and treatment compliance with angiotensin II receptor antagonists
Mancia, G., Seravalle, G., & Grassi, G. (2003) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2003.07.012 · Cited by 54
Peripheral and cerebrovascular atherosclerotic disease in diabetes mellitus
Mukherjee, D. (2009) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2008.10.015 · Cited by 52
Evidence for a Causal Role of Oxidative Stress in the Myocardial Complications of Insulin Resistance
Ritchie, R. H. (2009) · Heart Lung and Circulation · doi:10.1016/j.hlc.2008.11.003 · Cited by 54
Malik, R. A., Schofield, I. J., Izzard, A. S., Austin, C., Bermann, G., & Heagerty, A. M. (2005) · Hypertension · doi:10.1161/01.hyp.0000153305.50128.a1 · Cited by 51
Outcome beyond blood pressure control?
Staessen, J. A., Wang, J. G., & Birkenhäger, W. H. (2003) · European Heart Journal · doi:10.1016/s0195-668x(02)00797-2 · Cited by 51
Iwai, M., Kan‐no, H., Tomono, Y., Inaba, S., Senba, I., Furuno, M., Mogi, M., & Horiuchi, M. (2010) · Journal of Hypertension · doi:10.1097/hjh.0b013e32833bc420 · Cited by 50
DePaula, A. L., Stival, A. R., DePaula, C. C. L., Halpern, A., & Vencio, S. A. C. (2012) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-011-1807-0 · Cited by 51
Melmer, A., & Laimer, M. W. (2016) · Endocrine development · doi:10.1159/000439364 · Cited by 58
Cardiovascular Disease in Diabetes
Bloomgarden, Z. T. (2010) · Diabetes Care · doi:10.2337/dc10-zb04 · Cited by 56
Heart and Kidney: Fatal Twins?
Ritz, E. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.01.012 · Cited by 53
The cost of glucocorticoid-associated adverse events in rheumatoid arthritis
Pisu, M., James, N. I., Sampsel, S., & Saag, K. G. (2005) · Rheumatology · doi:10.1093/rheumatology/keh594 · Cited by 53
Diabetic renal disease: from recent studies to improved clinical practice
Mogensen, C. E., & Cooper, M. E. (2004) · Diabetic Medicine · doi:10.1111/j.1464-5491.2004.01121.x · Cited by 50
Blood Pressure and Cardiovascular Disease
Furberg, C. D., Psaty, B. M., & Soliman, E. Z. (2009) · Evidence‐Based Cardiology · doi:10.1002/9781444309768.ch13 · Cited by 48
Gallo, G., Volpe, M., & Rubattu, S. D. (2022) · Vascular Health and Risk Management · doi:10.2147/vhrm.s337640 · Cited by 62
Fonseca, V. A. (2006) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2006.05583.x · Cited by 50
Diabetes mellitus and hypertension: a dual threat
Oktay, A. A., Aktürk, H. K., & Jahangir, E. (2016) · Current Opinion in Cardiology · doi:10.1097/hco.0000000000000297 · Cited by 55
Rosen, A. B., Karter, A. J., Liu, J. Y., Selby, J. V., & Schneider, E. C. (2004) · Journal of General Internal Medicine · doi:10.1111/j.1525-1497.2004.30264.x · Cited by 50
Insulin resistance in hypertension and cardiovascular disease
Lamounier‐Zepter, V., Ehrhart‐Bornstein, M., & Bornstein, S. R. (2006) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2006.07.002 · Cited by 53
Nilsson, P. M., Guðbjörnsdóttir, S., Eliasson, B., & Cederholm, J. (2003) · Journal of Human Hypertension · doi:10.1038/sj.jhh.1001503 · Cited by 48
Luger, M., Holstein, B., Schindler, K., Kruschitz, R., & Ludvik, B. (2013) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0033-1341472 · Cited by 45
Liu, H., Liu, X., Wei, X., Chen, L., Xiang, Y., Yi, F., & Zhang, X. (2012) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2012.06.010 · Cited by 46
Uzu, T., Harada, T., Namba‐Hamano, T., Yamamoto, R., Takahara, K., Yamauchi, A., & Kimura, G. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000163156.37363.47 · Cited by 46
on behalf of the VART Investigators, Narumi, H., Takano, H., Shindo, S., Fujita, M., Mizuma, H., Kuwabara, Y., & Komuro, I. (2010) · Hypertension Research · doi:10.1038/hr.2010.186 · Cited by 46
RetractedDesai, A. S., & Fang, J. C.-T. (2008) · Heart Failure Clinics · doi:10.1016/j.hfc.2007.11.001 · Cited by 46
Tenenbaum, A., & Fisman, E. Z. (2004) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200404050-00001 · Cited by 50
Hypertension and antihypertensive treatment of diabetic nephropathy
Ritz, E., & Dikow, R. (2006) · Nature Reviews Nephrology · doi:10.1038/ncpneph0298 · Cited by 49
Cingolani, O. H., Yang, X.-P., Liu, Y.-H., Villanueva, M., Rhaleb, N.-E., & Carretero, O. A. (2004) · Hypertension · doi:10.1161/01.hyp.0000125013.22494.c5 · Cited by 45
Nishimura, T., Hashimoto, J., Ohkubo, T., Kikuya, M., Metoki, H., Asayama, K., Totsune, K., & Imai, Y. (2005) · Clinical and Experimental Hypertension · doi:10.1081/ceh-200067668 · Cited by 48
Higuchi, T., Abletshauser, C., Nekolla, S. G., Schwaiger, M., & Bengel, F. M. (2007) · Microcirculation · doi:10.1080/10739680701410827 · Cited by 44
Insights into the biology of diabetic vascular disease: What?s new?
Sowers, J. R., & Stump, C. S. (2004) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2004.08.007 · Cited by 47
Cea‐Calvo, L., Conthe, P., Gómez-Fernández, P., de Álvaro, F., & Fernández, C. (2006) · Cardiovascular Diabetology · doi:10.1186/1475-2840-5-23 · Cited by 49
Managing hypertension in type 2 diabetes mellitus
Horr, S. E., & Nissen, S. E. (2016) · Best Practice & Research Clinical Endocrinology & Metabolism · doi:10.1016/j.beem.2016.06.001 · Cited by 49
Kim, K., Ihm, S., Kim, G., Kim, H. C., Kim, J. H., Lee, H., Lee, J. H., Park, J. M., Park, S., Pyun, W. B., et al. (2019) · Clinical Hypertension · doi:10.1186/s40885-019-0123-y · Cited by 47
RENAAL Investigators, Boner, G., Cooper, M. E., McCarroll, K., Brenner, B. M., de Zeeuw, D., Kowey, P. R., Shahinfar, S., Dickson, T. Z., Crow, R. S., et al. (2005) · Diabetologia · doi:10.1007/s00125-005-1893-1 · Cited by 48
Islet amyloid, metabolic syndrome, and the natural progressive history of type 2 diabetes mellitus.
Hayden, M. R. (2002) · PubMed · Cited by 51
Parhofer, K. G., Münzel, F., & Krekler, M. (2007) · Cardiovascular Diabetology · doi:10.1186/1475-2840-6-36 · Cited by 44
Longevity‐related molecular pathways are subject to midlife “switch” in humans
Timmons, J. A., Volmar, C., Crossland, H., Phillips, B. E., Sood, S., Janczura, K. J., Törmäkangas, T., Kujala, U. M., Kraus, W. E., Atherton, P. J., et al. (2019) · Aging Cell · doi:10.1111/acel.12970 · Cited by 46
Angiotensin in atherosclerosis
Kon, V., & Jabs, K. (2004) · Current Opinion in Nephrology and Hypertension · doi:10.1097/00041552-200405000-00005 · Cited by 43
Embil, J. M., Albalawi, Z., Bowering, K., & Trepman, E. (2018) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2017.10.020 · Cited by 43
Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus
McGuire, D. K., Winterfield, J. R., Rytlewski, J., & Ferrannini, E. (2008) · Diabetes and Vascular Disease Research · doi:10.3132/dvdr.2008.011 · Cited by 44
Treating Elderly People with Diabetes and Stages 3 and 4 Chronic Kidney Disease
Abaterusso, C., Lupo, A., Ortalda, V., Biase, V. D., Pani, A., Muggeo, M., & Gambaro, G. (2008) · Clinical Journal of the American Society of Nephrology · doi:10.2215/cjn.00410108 · Cited by 49
Regulation of the renin-angiotensin system in coronary atherosclerosis: a review of the literature.
Hammoud, R., Vaccari, C. S., Nagamia, S. H., & Khan, B. V. (2007) · PubMed Central · Cited by 42
Cardioprotective medication use in hemodialysis patients
Miller, L., Hopman, W. M., Garland, J. S., Yeates, K., & Pilkey, R. M. (2006) · Canadian Journal of Cardiology · doi:10.1016/s0828-282x(06)70291-4 · Cited by 43
Use of an Olmesartan Medoxomil‐Based Treatment Algorithm for Hypertension Control
Neutel, J. M., Smith, D. H. G., Weber, M. A., Wang, A. C., & Masonson, H. N. (2004) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2006.03304.x · Cited by 42
Changing targets in the treatment of type 2 diabetes
Massi‐Benedetti, M. (2006) · Current Medical Research and Opinion · doi:10.1185/030079906x112714 · Cited by 45
Thornley-Brown, D. (2006) · Archives of Internal Medicine · doi:10.1001/archinte.166.7.797 · Cited by 42
Nemoto, S., Kobayashi, T., Taguchi, K., Matsumoto, T., & Kamata, K. (2011) · American Journal of Physiology-Heart and Circulatory Physiology · doi:10.1152/ajpheart.00178.2011 · Cited by 40
Ismail, H., Mitchell, R., McFarlane, S. I., & Makaryus, A. N. (2010) · Current Diabetes Reports · doi:10.1007/s11892-009-0081-y · Cited by 41
Busby, J., McMenamin, Ú., Spence, A., Johnston, B. T., Hughes, C., & Cardwell, C. R. (2018) · Alimentary Pharmacology & Therapeutics · doi:10.1111/apt.14388 · Cited by 40
ACE Inhibitors and Angiotensin II Receptor Antagonists
Dendorfer, A., Dominiak, P., & Schunkert, H. (2005) · Handbook of experimental pharmacology · doi:10.1007/3-540-27661-0_15 · Cited by 43
Endothelial dysfunction and hypertension in diabetes mellitus
Dandona, P., Chaudhuri, A., & Aljada, A. (2004) · Medical Clinics of North America · doi:10.1016/j.mcna.2004.04.006 · Cited by 42
Meredith, P. (2005) · American Journal of Cardiovascular Drugs · doi:10.2165/00129784-200505030-00004 · Cited by 45
Laverman, G. D., Remuzzi, G., & Ruggenenti, P. L. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000093368.27046.3c · Cited by 43
Risk Modification in Patients with Peripheral Arterial Disease: A Retrospective Survey
Youssef, F., Gupta, P., Mikhailidis, D. P., & Hamilton, G. (2005) · Angiology · doi:10.1177/000331970505600307 · Cited by 41
The cardiorenal syndrome in diabetes mellitus
Karnib, H. H., & Ziyadeh, F. N. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2010.05.022 · Cited by 43
The Role of Angiotensin II Type 1 Receptor Antagonists in Elderly Patients with Hypertension
Thomas, G. N., Chan, P., & Tomlinson, B. (2006) · Drugs & Aging · doi:10.2165/00002512-200623020-00004 · Cited by 47
Hypertension in people with Type 2 diabetes: knowledge‐based diabetes‐specific guidelines
Working Party of the International Diabetes Federation (European Region) (2003) · Diabetic Medicine · doi:10.1046/j.1464-5491.2003.01021.x · Cited by 44
Management of Blood Pressure in Patients With Diabetes
Grossman, E., & Messerli, F. H. (2011) · American Journal of Hypertension · doi:10.1038/ajh.2011.77 · Cited by 40
Monami, M., Filippi, L., Ungar, A., Sgrilli, F., Antenore, A., Dicembrini, I., Bagnoli, P., Marchionni, N., Rotella, C. M., & Mannucci, E. (2013) · Current Medical Research and Opinion · doi:10.1185/03007995.2013.772505 · Cited by 44
Loo, D. W. Y., Jiang, Y., Koh, K. W. L., Lim, F. P., & Wang, W. (2016) · Applied Nursing Research · doi:10.1016/j.apnr.2016.07.007 · Cited by 48
Atherogenesis--recent insights into basic mechanisms and their clinical impact
Schächinger, V., & Am, Z. (2002) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/17.12.2055 · Cited by 43
Gout and its comorbidities in the total population of Stockholm
Wändell, P. E., Carlsson, A. C., & Ljunggren, G. (2015) · Preventive Medicine · doi:10.1016/j.ypmed.2015.10.003 · Cited by 40
The Role of Renin–Angiotensin System in Diabetic Cardiomyopathy: A Narrative Review
Batista, J. P. T., de Faria, A. O. V., Ribeiro, T. F. S., & Silva, A. C. S. E. (2023) · Life · doi:10.3390/life13071598 · Cited by 44
Aronow, W. S. (2003) · Heart Disease · doi:10.1097/01.hdx.0000080714.87750.48 · Cited by 45
Ruilope, L. M., & Segura, J. (2003) · Clinical Therapeutics · doi:10.1016/s0149-2918(03)90091-9 · Cited by 42
Improvements in ECG accuracy for diagnosis of left ventricular hypertrophy in obesity
Rider, O. J., Ntusi, N., Bull, S., Nethononda, R. M., Ferreira, V. M., Holloway, C. J., Holdsworth, D., Mahmod, M., Rayner, J. J., Banerjee, R., et al. (2016) · Heart · doi:10.1136/heartjnl-2015-309201 · Cited by 46
Sowers, J. R., Neutel, J. M., Saunders, E., Bakris, G. L., Cushman, W. C., Ferdinand, K. C., Ofili, E., Weber, M. A., & on behalf of the INCLUSIVE Investigators (2006) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2006.05486.x · Cited by 39
Ihara, Y., Egashira, K., Nakano, K., Ohtani, K., Kubo, M., Koga, J., Iwai, M., Horiuchi, M., Gang, Z., Yamagishi, S., et al. (2007) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2007.07.044 · Cited by 38
Kjeldsen, S. E., Lyle, P. A., Kizer, J. R., Dahlöf, B., Devereux, R. B., Julius, S., Beevers, G., Fairé, U. D., Fyhrquist, F., Ibsen, H., et al. (2005) · Journal of Clinical Hypertension · doi:10.1111/j.1524-6175.2005.04254.x · Cited by 39
Self-citationManagement of diabetic hypertensives
Viswanathan, V., & Ganesh, J. (2011) · Indian Journal of Endocrinology and Metabolism · doi:10.4103/2230-8210.86982 · Cited by 46
Might losartan reduce sudden cardiac death in diabetic patients with hypertension?
Aronow, W. S. (2003) · The Lancet · doi:10.1016/s0140-6736(03)14208-0 · Cited by 38
Vogt, L., Navis, G. J., Köster, J., Manolis, A. J., Reid, J. L., & de Zeeuw, D. (2005) · Journal of Hypertension · doi:10.1097/01.hjh.0000186829.56372.04 · Cited by 45
Fisher, M. (2004) · Heart · doi:10.1136/hrt.2003.018622 · Cited by 41
Berl, T. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000093235.09769.9c · Cited by 40
Mancia, G. (2006) · American Journal of Hypertension · doi:10.1016/j.amjhyper.2005.10.009 · Cited by 39
Orlistat in the prevention of diabetes in the obese patient
Mancini, M. C. (2008) · Vascular Health and Risk Management · doi:10.2147/vhrm.s6808 · Cited by 37
Insulin Resistance as a Therapeutic Target for Chronic Kidney Disease
Teta, D. (2014) · Journal of Renal Nutrition · doi:10.1053/j.jrn.2014.10.019 · Cited by 42
Remonti, L. R., Dias, S., Leitão, C. B., Kramer, C. K., Klassmann, L. P., Welton, N. J., Ades, A. E., & Gross, J. L. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.04.020 · Cited by 38
Inverse agonism: the classic concept of GPCRs revisited [Review]
Sato, J., Makita, N., & Iiri, T. (2016) · Endocrine Journal · doi:10.1507/endocrj.ej16-0084 · Cited by 38
Antihypertensive medications: benefits of blood pressure lowering and hazards of metabolic effects
Karnes, J. H., & Cooper‐DeHoff, R. M. (2009) · Expert Review of Cardiovascular Therapy · doi:10.1586/erc.09.31 · Cited by 47
Metadata
- Authors
- Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., Lederballe-Pedersen, O., Nieminen, M. S., Omvik, P., Oparil, S., Wedel, H., Aurup, P., Edelman, J., & Snapinn, S.
- Affiliations
- University Hospital of Umeå (SE)
- Glostrup Hospital (DK)
- Sahlgrenska University Hospital (SE)
- Birmingham City Hospital (GB)
- Helsinki University Hospital (FI)
- University of Michigan (US)
- Oslo University Hospital (NO)
- Haukeland University Hospital (NO)
- University of Alabama at Birmingham (US)
- Nordic School of Public Health (SE)
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Lindholm, Lars H
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2002-03
- Volume
- 359
- Issue
- 9311
- Pages
- 1004-1010
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W1982920623
- Cited by
- 1,560
- References
- 31
- Citations by year
- 2026: 7 · 2025: 4 · 2024: 8 · 2023: 15 · 2022: 17 · 2021: 18 · 2020: 29 · 2019: 16 · 2018: 28 · 2017: 40 · 2016: 40 · 2015: 41 · 2014: 48 · 2013: 58 · 2012: 58
- FWCI
- 129.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Research Portal (Queen's University Belfast) (submittedVersion)
- UEA Digital Repository (University of East Anglia) (submittedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- losartan, atenolol, hypertension, diabetes mellitus, left ventricular hypertrophy, cardiovascular morbidity, cardiovascular mortality, antihypertensive drugs, ACE inhibitors, beta-blockers, LIFE trial, stroke, myocardial infarction, all-cause mortality, blood pressure reduction, Framingham risk score, electrocardiogram
- MeSH terms
- Aged, Aged, 80 and over, Antihypertensive Agents, Atenolol, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypertension, Male, Middle Aged, Regression Analysis, Losartan, Diabetes Complications, Angiotensin Receptor Antagonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.